Articles On Immutep (ASX:IMM)

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Biotechnology company Immutep (IMM) announces new interim data in its treatment of second line metastatic non-small cell lung carcinoma (NSCLC) patients from its Phase 2 TACTI-002 trial Key findings of the trial include a 73.7 per cent of...

The healthcare sector is Australia’s biggest employer, employing 1 in 7 Aussies or roughly two million people. Treasurer Josh Frydenberg announced last night that Australia’s health budget will top $132bn in 2022-23, up from $62bn a decade...

ASX set to rise as US tech stocks rally Sectors that got a big boost from Fed Budget include road and rail infrastructure ($18bn), defence ($15bn), and cybersecurity ($10bn) 5 ASX small caps to watch today: Immutep, Torque Metals, Elsight,...

Highlights Biotechnology companies research living organisms to develop drugs and other products. Investing in biotechnology stocks require due diligence and caution to make a profit and avoid loss. The S&P/ASX 200 Health Care ind...

Immutep (IMM) has recorded new data from second line non-small cell lung cancer (NSCLC) patients from its phase two TACTI-002 study The study is evaluating the combination of efti with Merck & Co’s KEYTRUDA treatment in patients with l...

ASX to open 0.6% lower Commodities bounce back as EU and US to discuss embargo on Russian energy Aussie dollar jumps to US75c ASX to dip, ban on Russian energy imminent Local shares are set to dip this morning after major stock indices on...

Biotech company Immutep (IMM) receives a patent from the Japanese Patent Office for LAG525 The patent is titled “antibody molecules to LAG-3 and uses thereof” and will expire on March 13, 2035 LAG525 is a humanised form of Immutep’s IMP701...

ASX biotech shares have, as a whole, had a remarkably poor run over the last 6 months. Here’s what we mean. Over the past 6 months, the All Ordinaries Index (ASX: XAO) is down 2.2%. Not what you’d like to see. But not close to gut wrenchin...

Immutep (IMM) receives “constructive feedback” from the US Food and Drug Administration (FDA) regarding its clinical development program for eftilagimod alpha (efti) The FDA is supporting Immutep’s view to continue exploring the developme...

ASX to rise as global equities rebound Wall Street and European stocks rebounded strongly overnight after Ukranian President Volodymyr Zelensky said he was open to compromise on some of Russia’s demands to end the war. At the close, all maj...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

Ms Turnbull rejoins Immutep’s board having previously served as its chair from October 2010 to November 2017.

ShareCafeBuying Opportunities Beckon Amid Biotech Bloodbath The sharp retreat in global biotech valuations is creating rare buying opportunities as investors flee ‘riskier’ sectors on the back of rising interest rates, dwindling liquidity a...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

Immutep (IMM) is granted a new patent by the Australian Patent Office The claims of the new patent protect Immutep’s intellectual property relating to combined therapeutic preparations, comprising its lead active immunotherapy candidate ef...

Venture capitalist Grant Chamberlain, a partner in Sydney VC OneVentures, has died after falling from a cliff in North Bondi. He was 50. Chamberlain joined OneVentures four years ago following two decades in merchant banking that included m...

With 2021 now officially behind us (at long last!), we asked our Foolish contributors to compile a list of some of the ASX shares experts are saying to buy in January. And, in case you missed it, don’t forget to also check out our coverage...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

ASX biotech shares were a mixed bag in 2021. Several of the majors came in behind their benchmarks whilst many smaller players outshone the pack. The sector has been the benefactor of long-term tailwinds in diagnostics and demand for nove...

With COVID-19 Omicron surging around the globe, ASX healthcare shares are back in the spotlight. While most don’t deal with the pandemic directly, there are many health and biotechnology companies on the ASX that are plugging away quietly...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

ShareCafeThe Week that Was – December 13-17, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do s...

Immutep (IMM) signs a manufacturing service agreement with Northway Biotech to manufacture its preclinical candidate for autoimmune diseases ahead of clinical testing Northway has already begun developing a manufacturing process for the dr...

The ASX 200 Health Index (XHJ) has dropped by almost 5% at the time of writing, compared to the broader index which is down by 0.20%. Healthcare giant and blood specialist, CSL (ASX:CSL), which makes up a large part of the ASX Healthcare in...

The Immutep Ltd (ASX: IMM) share price is rising today after news of a deal with a European company. Shares in Immutep were swapping hands at 47.5 cents in early morning trade, up 1.06%. Let’s take a look at what may be influencing the Im...

Immunotherapy development company Immutep (ASX:IMM) has signed a Manufacturing Service Agreement with Northway Biotech.

ShareCafeLatest from Immutep (ASX: IMM) on LAG-3 and 2022 Outlook Immutep (ASX: IMM) are global leaders in the understanding and development of therapeutics that relate to Lymphocyte Activation Gene-3 or “LAG-3” which is a cell surface mol...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

The Immutep Ltd (ASX: IMM) share price is in the red this morning, down 1.05% at the time of writing to 47 cents. The biotech company is developing LAG-3 related immunotherapy treatments for patients with cancer and autoimmune disease. Bel...

Immutep (IMM) has treated the first five patients in its study evaluating eftilagimod alpha (efti) in conjunction with standard of care chemotherapy  No additional safety signs were observed during the study, which is the first time a trip...

Wall Street falls further on Omicron fears The US stock markets once again fell heavily overnight, as the US confirmed its first case of the omicron variant. Cases of omicron in South Africa have doubled in two days, with the new strain als...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week At the time...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

Immutep (IMM) completes recruitment for its phase II study for non-small cell lung cancer The last patient has now been enrolled in the expansion stage of Part A of its Phase II TACTI-002 study Patients are now participating across three p...

The ASX 200 Health Index (XHJ) is up by 0.80% at the time of writing, compared to the broader index which is up by 0.30%. Immutep Limited (ASX:IMM) has has successfully completed patient recruitment for the Phase II TACTI-002 study of LAG-3...

Tech stocks gain on Wall Street US stocks were mixed overnight, but investors’ appetite were mainly focused on the tech sector. The Dow Jones retreated 0.17% , but the S&P 500 was up 0.34%, and tech heavy Nasdaq by 0.45%. Megatech stock...

The ASX 200 Health Index (XHJ) is up by 1.5% at the time of writing, compared to the broader index which is up by 0.40%. Mesoblast (ASX:MSB) jumped 10% after reporting data from its Phase 3 trial of rexlemestrocel-L in chronic heart failure...

Wall Street was lower for the week US stocks rebounded on Friday, but finished the week lower after an inflation data-triggered selloff on Wednesday. All three US stocks benchmarks rose, led by tech – the Dow Jones by 0.5%, the S&P 500...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The AGM sea...

Despite what Immutep’s two-day sell-off may have you thinking, now is the time the biotech giants are going to do due diligence on Marc Voigt’s LAG-3 bet.

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has followed the lead of US markets and is trading lower. At the time of writing, the benchmark index is down 0.1% to 7,425.7 points. Four ASX shares that are falling more than most...

Shares in Australian biotechnology company Immutep Ltd (ASX: IMM) are tanking on Wednesday morning, down 20% to 56 cents. Immutep shares are on the move this morning after the company announced data from a Phase IIb trial on its lead drug...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

Intelicare nabs MercyCare contract for its AI sensor tech Telix scores TGA approval for prostate cancer imaging product MGC receives Israeli approval for COVID treatment dosing study   Intelicare Holdings (ASX:ICR) Intelicare jumped 35.4...